External Link - Source: The New York Times
Doctors welcomed federal approval this week of a new, fast-acting nasal spray for depression. But also they expressed concerns about its cost and long-term effects, as well as the logistics of administering it in accordance with safety requirements.
The new drug, esketamine, made by Janssen Pharmaceuticals, won approval from the Food and Drug Administration on Tuesday for people who have received little or no relief from other antidepressants. The F.D.A.’s decision followed months of anticipation; esketamine, which will be marketed under the name Spravato, is the first prescription for depression derived from ketamine, an old and widely used anesthetic.